<DOC>
	<DOCNO>NCT01649466</DOCNO>
	<brief_summary>This study design evaluate safety efficacy vildagliptin versus NPH insulin add-on glimepiride patient type 2 diabetes mellitus reach adequate glycemic control current sulfonylurea monotherapy give treat physician guidance additional anti-diabetic treatment use sulfonylurea monotherapy sufficient reach glycemic control .</brief_summary>
	<brief_title>Safety Efficacy Vildagliptin Versus NPH Insulin add-on Glimepiride Type 2 Diabetes Mellitus Patients .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Confirmed diagnosis type 2 diabetes mellitus . Contraindicated intolerant take metformin . HbA1c ≥ 7.0 % ≤ 8.5 % Current sulfonylurea ( glimepiride ) monotherapy judge investigator inadequately control Other protocoldefined inclusion/exclusion criterion may apply Patients take antidiabetes drug ( oral injection ) SU component precede 12 week . Acute metabolic condition ketoacidosis , lactic acidosis hyperosmolar state within past 6 month Patients take sulfonylurea longer 5 year History hypersensitivity study drug drug similar chemical structure pregnancy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes mellitus , diabetes</keyword>
</DOC>